ClinicalTrials.gg
RecruitingNCT06772077Updated Aug 14, 2025

Safety and Usability of the ATLAS 2030 Exoskeleton in Pediatric Patients With Spinal Cord Injury

An interventional study of Rehabilitation treatment with ATLAS2030 in Spinal Cord Injury (SCI), sponsored by MarsiBionics. Recruiting at 1 site in Spain. Open to participants aged 3 Years to 14 Years. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by MarsiBionics · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
3 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Spinal Cord Injuries with a site in Spain — 11 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.

Planned enrollment
34th of 55
20 · median 30
Started
2025
with 4 others
No phase
34 of 59
8 open now
Primary completion
2026-02
later than 4 of 12 live
Registered
49th of 59
by date
Lead sponsor
4 of 59
MarsiBionics

Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 34th largest by planned enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2025, is one of 34 with no phase, reaches primary completion later than 4 of the 12 other live ones, and was the 49th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

11 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 3 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Spinal Cord Injuries with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to analyze the usability and safety of the robotic gait ATLAS 2030 in a cohort of pediatric patients with Spinal Cord Injury, with the aim of extending its indication for use to pediatric spinal cord injury

Read the detailed description

Spinal cord injury has a relatively low prevalence in the pediatric population, although its effects have significant physical and psychological consequences that greatly impact the quality of life of affected children. The ATLAS 2030 exoskeleton is a robotic gait device approved by the Spanish Agency of Medicines and Medical Devices for the rehabilitation of pediatric patients with cerebral palsy and spinal muscular atrophy. The principal aim is to analyze the safety and usability of the ATLAS 2030 exoskeleton during the implementation of a robotic gait training program with this device in a cohort of pediatric patients with spinal cord injury. the secondary aim is to analyze, in the same cohort of pediatric patients with spinal cord injury and through the implementation of the same therapeutic program, the efficacy of the ATLAS 2030 exoskeleton in improving fatigability, mood, health perception, and gait speed.

Ten sessions with the ATLAS 2030 exoskeleton will be conducted with pediatric patients with acute or chronic spinal cord injury. Additionally, two assessment sessions will be performed before and after the series of sessions.

03

Conditions studied

  • Spinal Cord Injury (SCI)

Keywords

  • Spinal Cord Injury
  • Rehabilitation
  • robotics
  • Gait Exoskeleton
  • children
  • ATLAS2030
04

Who can participate

Ages eligible
3 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having a subacute or chronic spinal cord injury (SCI) and being clinically stable with a general condition good enough to participate in the therapeutic program with the ATLAS 2030.
  • Age between 3 and 14 years.
  • Medical authorization to perform standing and gait training with weight-bearing.
  • Consent from the participant or legal guardian to participate in the study.
  • Adequate level of acceptance and commitment from the family.

Inclusion criteria related to device characteristics:

  • Weight ≤ 35 kg.
  • Hip width ≤ 34 cm. It is advised that for measurements under 28 cm, verification should be performed to ensure there is no excessive base of support that might induce foot inversion in the standing position.
  • Femur length (distance from the greater trochanter to the lateral condyle of the femur) between 24 cm and 33 cm. Femur lengths shorter than 24 cm are acceptable as long as the hip motor of the device does not extend above the user's iliac crest, avoiding hypermobility of the lumbar spine.
  • Tibia length (distance from the lateral condyle to the lateral malleolus of the tibia) between 23 cm and 32 cm. Tibia lengths shorter than 23 cm are acceptable as long as they can be compensated with a lift and the user's ankle joint remains within the area of the ankle motor.
  • EU shoe size between 27 and 33.

Exclusion criteria

Exclusion Criteria:

  • Impossibility for the family to complete treatment schedule planning.
  • Any for standing and/or walking.
  • Spasticity (Modified Ashworth Scale (MAS) = 4 in the lower limbs at the time of device use).
  • Joint contracture of the hip and/or knee > 20 degrees.
  • Need to walk with more than 9 degrees of hip abduction.
  • Need to walk with more than 9 degrees of dorsal or plantar ankle flexion, or inability to use an orthosis to achieve 90° at the ankle.
  • Severe skin lesions in areas of contact with the device.
  • Planned surgical intervention during the study period or previous orthopedic surgery on the spine and/or lower limbs contraindicating treatment.
  • Known advanced osteoporosis evidenced by bone densitometry, particularly with a history of prior fractures or fractures without trauma. Traumatic bone fractures in the lower limbs or pelvic girdle within the past 6 months.
  • Unstable fractures, joint dislocations, or other joint pathologies in the trunk and lower limbs contraindicating the treatment.
  • Severe rigid orthopedic deformities of the spine that prevent the use of the device.
  • Presence of frequent seizures, uncontrolled epilepsy, or difficult-to-control behavioral disorders.
  • Presence of decompensated heart or lung disease, or any other condition causing exercise intolerance.
  • Allergy to any of the materials used in the ATLAS 2030: cotton, nylon, polyester, polyamide, polyethylene, or polypropylene.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Robot Asissted Gait Training

    The rehabilitation sessions will be carried out by a physiotherapist trained in rehabilitation with the ATLAS 2030 exoskeleton

    Device: Rehabilitation treatment with ATLAS2030

Interventions

  • DeviceRehabilitation treatment with ATLAS2030

    10 sessions of Rehabilitation Treatment with ATLAS2030 with With an evaluation session before the first session and another one after 10 sessions.

    Also known as: Robot Asissted Gait rehabilitation

06

What researchers measure

Primary outcomes

  1. Serious Adverse Events

    occurrence of any serious adverse event to the participant

    Time frame: From enrollment to the last assessment session at 8 weeks

  2. Falls prevalence

    Number of falling events occurred from the participant or caregiver

    Time frame: From enrollment to the last assessment session at 8 weeks

  3. Skin integrity

    Occurrence of any injury of the skin in the areas of contact and produced by the use of the device

    Time frame: From enrollment to the last assessment session at 8 weeks

  4. Pain assessment

    pain measured by the Visual Analogic Scale (VAS) by the participant, scored from 0 to 10, being 0 "no pain" and 10 "unbearable pain"

    Time frame: From enrollment to the last assessment session at 8 weeks

  5. Heart rate

    measurement of heart rate

    Time frame: from the beginning to the end of treatment at 6 weeks

  6. Oxygen saturation

    measurement of Oxygen saturation when medical prescription

    Time frame: from the beginning to the end of treatment at 6 weeks

  7. Blood pressure

    measurement of blood pressure. Systolic and diastolic pressures will be assessed

    Time frame: from the beginning to the end of treatment at 6 weeks

  8. User and/or caregiver perception of the device

    Questions that are scored from 0 to 5 on aspects related to comfort, weight, volume, etc

    Time frame: From enrollment to the last assessment session at 8 weeks

  9. Device usage data

    Total walking time. Unit of Measure: Minutes.

    Time frame: From enrollment to the last assessment session at 8 weeks

  10. Number of steps

    Number of steps with the device

    Time frame: From enrollment to the last assessment session at 8 weeks

  11. Usage modes

    two different usage modes (active and automatic).

    Time frame: From enrollment to the last assessment session at 8 weeks

  12. Speed

    speed achieved with the device (steps per minute)

    Time frame: From enrollment to the last assessment session at 8 weeks

  13. Range of motion

    Passive Degree to which a joint can move (hip, knee, and ankle joints in both legs). From 0º to 180º.

    Time frame: From enrollment to the last assessment session at 8 weeks

Secondary outcomes

  1. State of mind

    It will be done with a Likert-type scale from 1 to 5 (1: very sad; 2: sad; 3: indifferent; 4: happy; 5: very happy). This scale will be administered before and after each therapeutic session.

    Time frame: from the beginning to the end of treatment at 6 weeks

  2. Health perception

    EQ-5D scale assesses five dimensions of health: Mobility, Self-care, Usual activities, Pain/Discomfort, and Anxiety/Depression. Each dimension has five levels of severity (No problems, Slight problems, Moderate problems, Severe problems, and Extreme problems).

    Time frame: from enrollment to the last assessment session at 8 weeks

  3. Health perception

    Visual Analogue Scale (VAS) is a vertical scale where patients rate their current health on a scale from 0 to 100 (0 representing "the worst health you can imagine" and 100 representing "the best health you can imagine.

    Time frame: from enrollment to the last assessment session at 8 weeks

  4. 10 Meter Walking Test (10 MWT) measured with ATLAS 2030

    The 10 Meter Walking Test (10MWT) records the time taken by the participant to walk 10 meters with the device in motion intent mode.

    Time frame: From enrollment to the last assessment session at 8 weeks

  5. Effort perception

    Borg Rating of Perceived Exertion (RPE), is a tool used to measure the intensity of physical activity based on how hard you feel your body is working. \- Modified Borg Scale (0-10): This version ranges from 0 to 10, where 0 means "nothing at all" and 10 means "very, very hard." It's often used in clinical settings to assess symptoms like breathlessness, chest pain, and muscle fatigue.

    Time frame: from the beginning to the end of treatment at 6 weeks

Other outcomes

  1. Classification of Spinal Cord Injury

    The International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) is a standardized tool for assessing and classifying spinal cord injuries Sensory function: Assessed in 28 dermatomes per side for light touch and pinprick sensations, scored as 0 (absent), 1 (impaired), or 2 (normal). Maximum score: 224 points (112 per modality). Motor function: Evaluated in 10 key muscle groups per side, using a 0-5 strength scale. Maximum score: 100 points. ASIA Impairment Scale: Classifies the severity of spinal cord injury into five categories: from A (complete) to E (normal).

    Time frame: From enrollment to the last assessment session at 8 weeks

  2. Disability

    The Spinal Cord Independence Measure (SCIM) III. It is composed of 19 items that assess three main domains: * Self-care (6 items, scores range from 0-20) * Respiration and sphincter management (4 items, scores range from 0-40) * Mobility (9 items, scores range from 0-40) The total SCIM scores range from 0 to 100

    Time frame: From enrollment to the last assessment session at 8 weeks

  3. Walking ability

    WISCI II (Walking Index for Spinal Cord Injury): Assess walking ability and level of assistance needed. Scoring: 0: Cannot walk. 20: Independent walking. Intermediate (1-19): Varies with assistive devices.

    Time frame: From enrollment to the last assessment session at 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Hospital Nacional Parapléjicos
    Toledo, 45004, Spain
    Recruiting
    • Elisa, López-Dolado · Contactelopez@sescam.jccm.es · 925247700
    • Raquel Madroñero-Mariscal · Sub investigator
    • Inés García de la Torre Soto · Sub investigator
    • Almudena Valiente Úbeda · Sub investigator
    • Ana de los Reyes Guzmán · Sub investigator
    • Ana Escobar Corroto · Sub investigator
    • Elisa López-Dolado · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2026, 12 months after the start.

Of 49 industry-sponsored interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 12 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2024
First posted
Jan 13, 2025
StartActual
Feb 17, 2025
Primary completionEst.
Feb 2026
CompletionEst.
Feb 1, 2026
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06772077
Lead sponsor
MarsiBionics
Collaborators
Hospital Nacional de Parapléjicos de Toledo, Fundación del Lesionado Medular
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Feb 17, 2025
Primary completion
Feb 2026 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Aug 14, 2025

Study contacts

Carlos Cumplido Trasmonte
Contact
carlos.cumplido@marsibionics.com
0034 914900090
Elisa López-Dolado
Contact
0034 925247700

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion